vs
Side-by-side financial comparison of STAG Industrial, Inc. (STAG) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($311.4M vs $224.2M, roughly 1.4× STAG Industrial, Inc.). STAG Industrial, Inc. runs the higher net margin — 27.6% vs 16.4%, a 11.2% gap on every dollar of revenue. On growth, STAG Industrial, Inc. posted the faster year-over-year revenue change (9.1% vs -1.5%). Over the past eight quarters, STAG Industrial, Inc.'s revenue compounded faster (8.7% CAGR vs 1.3%).
Stag Arms is a firearms manufacturer founded in May 2003 and located in Cheyenne, Wyoming. Stag Arms is a manufacturer of the AR-15 type rifle, marketed as Stag-15 rifles. Stag advertises that all their weapons and accessories are made in the United States. They are best known for their left-handed AR-15 rifles, which use a mirror imaged upper receiver and have the ejection port reversed for left-handed shooters and the safety selector control on the right side of the lower receiver.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
STAG vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $224.2M | $311.4M |
| Net Profit | $62.0M | $51.0M |
| Gross Margin | — | 66.9% |
| Operating Margin | — | 24.2% |
| Net Margin | 27.6% | 16.4% |
| Revenue YoY | 9.1% | -1.5% |
| Net Profit YoY | — | 126.0% |
| EPS (diluted) | $0.32 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $224.2M | $311.4M | ||
| Q4 25 | $220.9M | $295.9M | ||
| Q3 25 | $211.1M | — | ||
| Q2 25 | $207.6M | $317.0M | ||
| Q1 25 | $205.6M | $316.2M | ||
| Q4 24 | $199.3M | $297.0M | ||
| Q3 24 | $190.7M | $289.5M | ||
| Q2 24 | $189.8M | $306.1M |
| Q1 26 | $62.0M | $51.0M | ||
| Q4 25 | $83.5M | $38.0M | ||
| Q3 25 | $48.6M | — | ||
| Q2 25 | $50.0M | $-17.7M | ||
| Q1 25 | $91.4M | $22.6M | ||
| Q4 24 | $51.0M | $34.9M | ||
| Q3 24 | $41.9M | $33.6M | ||
| Q2 24 | $59.8M | $40.6M |
| Q1 26 | — | 66.9% | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | 24.2% | ||
| Q4 25 | — | 18.4% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -7.5% | ||
| Q1 25 | — | 12.2% | ||
| Q4 24 | — | 16.0% | ||
| Q3 24 | — | 13.8% | ||
| Q2 24 | — | 15.0% |
| Q1 26 | 27.6% | 16.4% | ||
| Q4 25 | 37.8% | 12.8% | ||
| Q3 25 | 23.0% | — | ||
| Q2 25 | 24.1% | -5.6% | ||
| Q1 25 | 44.5% | 7.1% | ||
| Q4 24 | 25.6% | 11.7% | ||
| Q3 24 | 21.9% | 11.6% | ||
| Q2 24 | 31.5% | 13.3% |
| Q1 26 | $0.32 | $0.32 | ||
| Q4 25 | — | $0.24 | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.14 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | — | $0.21 | ||
| Q2 24 | — | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $8.9M | $209.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.6B | $2.1B |
| Total Assets | $7.2B | $2.6B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $8.9M | $209.8M | ||
| Q4 25 | $14.9M | $172.9M | ||
| Q3 25 | $17.3M | — | ||
| Q2 25 | $15.4M | $162.2M | ||
| Q1 25 | $9.3M | $140.7M | ||
| Q4 24 | $36.3M | $177.5M | ||
| Q3 24 | $70.0M | $187.5M | ||
| Q2 24 | $33.3M | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | $3.3B | $260.0M | ||
| Q3 25 | $3.1B | — | ||
| Q2 25 | $3.0B | $346.0M | ||
| Q1 25 | $3.0B | $330.0M | ||
| Q4 24 | $3.0B | $300.0M | ||
| Q3 24 | $2.9B | $300.0M | ||
| Q2 24 | $2.8B | $319.0M |
| Q1 26 | $3.6B | $2.1B | ||
| Q4 25 | $3.6B | $2.0B | ||
| Q3 25 | $3.4B | — | ||
| Q2 25 | $3.4B | $1.9B | ||
| Q1 25 | $3.5B | $2.0B | ||
| Q4 24 | $3.5B | $2.1B | ||
| Q3 24 | $3.3B | $2.1B | ||
| Q2 24 | $3.3B | $2.1B |
| Q1 26 | $7.2B | $2.6B | ||
| Q4 25 | $7.2B | $2.5B | ||
| Q3 25 | $6.9B | — | ||
| Q2 25 | $6.8B | $2.6B | ||
| Q1 25 | $6.8B | $2.6B | ||
| Q4 24 | $6.8B | $2.7B | ||
| Q3 24 | $6.6B | $2.7B | ||
| Q2 24 | $6.4B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.91× | 0.13× | ||
| Q3 25 | 0.91× | — | ||
| Q2 25 | 0.88× | 0.18× | ||
| Q1 25 | 0.87× | 0.16× | ||
| Q4 24 | 0.88× | 0.14× | ||
| Q3 24 | 0.89× | 0.14× | ||
| Q2 24 | 0.84× | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
STAG
Segment breakdown not available.
TECH
| Protein Sciences segment revenue | $226.2M | 73% |
| Diagnostics and Spatial Biology segment revenue | $85.6M | 27% |
| Other revenue (1) | $5.4M | 2% |
